Cardiovascular Diabetology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2024-04-13 ms5000001142047044 来自山东省

偏重的研究方向：代谢综合征
经验分享：请问各位大佬，peer review是送审了吗

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-03-16 ms5000001279026069 来自福建省

偏重的研究方向：心血管;主动脉夹层
经验分享：想问下大家，不是做糖尿病可以投吗

619 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2024-03-08 ms1000000262909438 来自湖北省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病心血管
经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍

414 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-11-24 ms6000000946453986 来自山东省

偏重的研究方向：血脂;糖尿病
经验分享：有没有被接受的基础研究文章啊

446 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-10-10 ms8000000183026287 来自德国

10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。

472 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-12-25 好吃猫111 来自广东省

甲状腺激素的可以投么？

382 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2022-01-16 123zz123

偏重的研究方向：临床队列
经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗

3974 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-06-25 ms8000001858743317 来自北京

有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高

575 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-04-12 ms8000001858743317 来自北京

请问大家初始技术审查大概持续多久

559 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198288, encodeId=bebf219828868, content=偏重的研究方向：代谢综合征 经验分享：请问各位大佬，peer review是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4eb18429497, createdName=ms5000001142047044, createdTime=Sat Apr 13 15:04:33 CST 2024, time=2024-04-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2170716, encodeId=0ec321e071678, content=偏重的研究方向：血脂;糖尿病 经验分享：有没有被接受的基础研究文章啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94878476721, createdName=ms6000000946453986, createdTime=Fri Nov 24 11:41:13 CST 2023, time=2023-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=472, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=2177085, encodeId=b5a521e7085fe, content=甲状腺激素的可以投么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=好吃猫111, createdTime=Mon Dec 25 14:42:01 CST 2023, time=2023-12-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2125405, encodeId=19982125405b2, content=请问大家初始技术审查大概持续多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=559, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Wed Apr 12 10:52:43 CST 2023, time=2023-04-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省)]

2023-03-28 123d2a9fm15暂无昵称来自湖南省

想请问已投过的大神们，peer review 的状态是送审了吗

621 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务